Varenicline with nicotine lozenges and a phone support program to help adults quit smoking
A Randomized Factorial Trial of Varenicline with Nicotine Lozenges and a Smartphone Medication Adherence Intervention to Promote Smoking Cessation
This project compares varenicline alone to varenicline plus nicotine lozenges and a smartphone medication-support program to help adults 21 and older stop smoking.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project ID | NIH-11248834 on NIH RePORTER |
What this research studies
You would be an adult smoker (21+) taking varenicline and may also be randomly assigned to use nicotine lozenges and a smartphone-based medication adherence program. The trial uses a factorial design so participants can receive one, both, or neither of the additional supports. The smartphone program provides reminders and tips to help with taking medication and handling cravings, and researchers will track your smoking status with follow-up visits and biochemical tests. The study aims to see whether adding lozenges and phone support improves quit rates compared with varenicline alone.
Who could benefit from this research
Good fit: Adults aged 21 or older who smoke, want help quitting, are willing to take varenicline, and have access to a smartphone are ideal candidates.
Not a fit: People who cannot take varenicline, are under age 21, or do not have smartphone access may not be eligible or benefit from this program.
Why it matters
Potential benefit: If successful, this approach could help more people quit by reducing cravings and improving use of medication.
How similar studies have performed: Meta-analyses show that varenicline plus the nicotine patch can boost quit rates, but varenicline combined with nicotine lozenges has not been tested in randomized trials and the smartphone adherence approach is relatively new.
Where this research is happening
Oklahoma City, United States
- University of Oklahoma Hlth Sciences Ctr — Oklahoma City, United States (Active)
Researchers
- Principal investigator: Kendzor, Darla Elizabeth — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Kendzor, Darla Elizabeth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.